Promising Phase III Data For Roche/Ipsen's Taspoglutide Heats Up GLP-1 Race
This article was originally published in The Pink Sheet Daily
Executive SummaryOnce-weekly human GLP-1 analog taspoglutide shows superior HbA1c reduction to Byetta - and may soon catch Novo's liraglutide.
You may also be interested in...
It has been a bumpy ride for some of the (still modest) number of European biotechs listed on Nasdaq, for various reasons. Yet most expect the direct-to-Nasdaq trend to continue. Europe’s public markets simply cannot compete.